MANHATTAN BEACH, Calif., Oct. 22, 2015 /PRNewswire-USNewswire/ — Today, The U.S. Food and Drug Administration (FDA) approved a novel therapy for patients with metastatic pancreatic adenocarcinoma – the most common form of pancreatic cancer – whose disease has progressed following gemcitabine-based therapy, offering new hope against a disease that will claim …